Traders should position for high volatility ahead of the May 18 data announcement. Positive Phase 1/2 data in Friedreich's ataxia could trigger a significant rally, while negative results would likely lead to a sharp decline. Consider straddle or strangle options strategies to capture the binary outcome.
Price Chart
Executive Summary
Design Therapeutics will announce Phase 1/2 RESTORE-FA trial data for DT-216P2 in Friedreich's ataxia on May 18, 2026. This is a binary catalyst for the stock, as positive data could validate the platform and drive significant upside, while negative data would be highly detrimental given the company's clinical-stage profile.
Key Facts
- Data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in Friedreich's ataxia will be announced on May 18, 2026.
- Management will host a conference call and webcast at 8:00 a.m. ET on the same day.
- Design Therapeutics is a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases.
- The stock has a market cap of $898M and 92% analyst bullish rating.
Financial Impact
Binary event; positive data could drive 50-100% upside given early-stage biotech dynamics, while negative data could result in 50-80% downside.
Risk Factors
- Negative or inconclusive Phase 1/2 data could lead to a severe stock price decline.
- The company is clinical-stage with no approved products, making it highly dependent on this trial outcome.
- Market expectations may already be priced in, limiting upside surprise.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296269 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 3, 2026 12w ago | 8-K | $12.76 $15.09 | ▲ +18.26% | ▲ +17.02% | $10.40 (−18.50%) |
Aug 3, 2026 12w ago | Press Release | $12.76 $15.09 | ▲ +18.26% | ▲ +17.02% | $10.40 (−18.50%) |
May 18, 2026 23w ago | 8-K | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.40 (−2.80%) |
May 18, 2026 23w ago | Press Release | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.40 (−2.80%) |
May 17, 2026 23w ago | Press Release | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.40 (−2.80%) |
Apr 28, 2026 25w ago | Press Release | $15.79 $11.10 | ▼ −29.70% | ▼ −35.16% | $10.40 (−34.14%) |
Apr 23, 2026 26w ago | DEFA14A | $12.53 $11.01 | ▼ −12.13% | ▼ −16.16% | $10.40 (−17.00%) |
Apr 1, 2026 29w ago | 3 | $11.23 $13.60 | ▲ +21.10% | ▲ +11.23% | $10.40 (−7.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers